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rats. However, there have been no clinical trials of its effect in patients with diarrhea and ir-
ritable bowel syndrome (IBS-D). We performed a randomized, double-blind, placebo-controlled
trial to determine whether ramosetron reduces diarrhea in these patients.METHODS: Our study included 296 male outpatients with IBS-D treated at 52 centers in Japan. Patients
were given 5 mg oral ramosetron (n[ 147) or placebo (n[ 149) once daily for 12 weeks after a
1-week baseline period. The primary end point was increased stool consistency in the ﬁrst
month. Secondary end points included relief of overall IBS symptoms and increased IBS-related
quality of life.RESULTS: More patients given ramosetron (74, 50.3%) than those given placebo (29, 19.6%) reported
improved stool consistency in the ﬁrst month (P < .001). The relative risk and number needed
to treat were 2.57 (95% conﬁdence interval, 1.79–3.70) and 3.25 (95% conﬁdence interval,
2.44–4.89), respectively. The ramosetron group had signiﬁcantly higher monthly rates of relief
of overall IBS symptoms and IBS-related quality of life than the placebo group.CONCLUSIONS: Ramosetron (5 mg oral, once daily for 12 weeks) improved stool consistency in male patients
with IBS-D, compared with placebo. These study results, along with the pharmacologic proﬁle of
ramosetron, indicate that increased stool consistency is the best end point for studies of
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Irritable bowel syndrome (IBS) is a representativefunctional gastrointestinal disorder1 that impacts
patients’ lives, themedical economy, andmodern society.2
IBS is very common in the general population, with an
estimated prevalence of 10%–20% in North America3 and
2.9%–15.6% in Asia,4 and it considerably compromises
health-related quality of life (HR-QOL) of the patients.5
Nonetheless, treatments for IBS are unsatisfactory, and
only 22% of IBS patients receiving usual medical care
have reported at least 50%reduction inbowel symptoms.6
The Rome III criteria classify the IBS phenotype into 4
groups7: IBS with diarrhea (IBS-D), IBS with constipation
(IBS-C), mixed IBS, and unsubtyped IBS. However, this
symptomatic phenotyping does not guarantee etiologic and
pathophysiological homogeneity of IBS.8 Some evidence
suggests that 5-hydroxytryptamine ([5-HT], serotonin) has
a crucial role in IBS-D pathophysiology. IBS-D patients have
exaggerated colonic motility in response to colorectaldistention.9 The distention-induced peristaltic reﬂex is
mediated by 5-HT.10 The 5-HT secretion is exaggerated in
IBS-D, but not IBS-C, patients.11 Abnormal neurotransmis-
sion of 5-HT via the 5-HT receptor 3 (5-HT3) has been re-
ported in IBS-D patients.12 Use of 5-HT3 antagonist for
IBS-D patients is logical consequence, and alosetron
showed distinct efﬁcacy on symptoms of IBS-D.13 More-
over, meta-analysis of a large patient cohort indicated that
5-HT3 antagonists achieve global improvement in IBS
symptoms and relieve abdominal pain and discomfort.14
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alosetron, has limited the use of this drug.15
Ramosetron, a 5-HT3 antagonist with high potential
and selectivity,16 clearly reduced stress-induced diarrhea
and defecation caused by corticotropin-releasing hor-
mone in rats.17,18 Distinct beneﬁts of ramosetron were
previously observed in a global assessment of relief of
overall IBS symptoms.19,20 However, several issues need
to be addressed. First, the effect of ramosetron on stool
form as a primary end point requires investigation. The
United States Food and Drug Administration (FDA)
proposed a study design for clinical trials focused on
IBS,21 suggesting use of abdominal pain and stool con-
sistency as co-primary end points for IBS-D. However,
the guidance permits trials of drugs that target only one
of these end points if the mechanism of action of the drug
applies to only one of these symptoms. Ramosetron
primarily improves stool consistency and has been
approved by regulatory authorities in Japan,20,22 Korea,23
and Thailand. The phase II,19 III,20 and open-labeled23
studies reported improvement in stool consistency as a
secondary end point. As FDA recommended, it is neces-
sary to examine whether ramosetron performs well on
stool consistency as the primary end point. Other key
efﬁcacy end points should be assessed as secondary end
points. Second, the effect of ramosetron on HR-QOL must
be established. Only one published report shows that 5-
HT3 antagonists improve disease-speciﬁc HR-QOL in fe-
male IBS-D patients.24 Moreover, male IBS-D patients
have been largely ignored in most clinical trials of 5-HT3
antagonists in Western countries. Clinical trials in male
patients are important for increasing medical knowledge
about the effects of these drugs on IBS-D. Thus, this
study examined the effects of ramosetron on stool con-
sistency in male IBS-D patients, testing the hypothesis
that ramosetron is superior to placebo in improving stool
consistency, with a low incidence of serious adverse
events. The effects of ramosetron on HR-QOL were also
veriﬁed.Methods
Patient Population
This study was conducted from October 2010–August
2011 at 52 centers with departments of gastroenterology
in Japan. Male outpatients aged 20–64 years and diag-
nosed according to the Rome III criteria7 were eligible.
The study protocol was designed in accordance with the
Declaration of Helsinki and was approved by institu-
tional review boards at all sites. All patients provided
written informed consent before participating in study-
related procedures.
Patients satisfying the inclusion and exclusion criteria
were monitored during a 1-week baseline period in
which data on severity of abdominal pain/discomfort
and stool consistency were collected to ensure thatpatients met the criteria. Severity of abdominal pain/
discomfort was assessed daily on a 5-point ordinate
scale. Stool consistency was classiﬁed by using the
Bristol Stool Form Scale (BSFS).7 Patients who had not
used drugs or undergone examinations that could affect
the evaluation of study drug efﬁcacy within 10 days
before randomization; who recorded all items in the
patient diary for 5 days during the baseline period;
who had mean severity scores of abdominal pain/
discomfort of 0.7 during the baseline period; in whom
no type 1 or 2 stool form, as scored by BSFS, was
recorded during the baseline period; who had bowel
movements for 5 days, with a mean score of >5 on
BSFS during the baseline period; and who were not
judged ineligible for the study according to the clinical
laboratory test results received before the baseline
period were randomized and successively administered
treatment (Supplementary Material).Study Design
This randomized, double-blinded, placebo-controlled,
clinical trial comprised a provisional registration period,
a 1-week baseline period, and a 12-week treatment
period, similar to previous studies.19,20 After the baseline
period, eligible patients were randomly assigned to 12-
week oral treatments with placebo or ramosetron hy-
drochloride (5 mg once daily) before breakfast. Visits
were scheduled at weeks 2, 4, 8, and 12 (or at discon-
tinuation) to assess treatment efﬁcacy, drug compliance,
and occurrence of adverse events. Randomization was
performed in a 1:1 ratio by using a block size of 4 with a
Web-based randomization system. All patients, in-
vestigators, and sponsors were blinded until all obser-
vations and evaluations were completed, statistical
analysis plans were ﬁnalized, and all data had been
entered. All authors had access to the study data and had
reviewed and approved the ﬁnal manuscript.Data Collection
During the baseline and treatment periods, patients
recorded their IBS symptoms daily on paper diary cards
at bedtime and electronically entered data into a database
daily by using an interactive voice response system to
support completion of data entry in the paper diary cards
every day. This system of evaluating IBS symptoms has
been previously reported as reliable and valid.19,20 In the
diary, patients recorded BSFS types and stool frequencies
and scored the severity of their abdominal pain/discom-
fort on the 5-point ordinate scale. Urgency and feelings of
incomplete evacuation were assessed on a binary scale.
Every 7 days during the treatment period, patients also
assessed the degree to which they experienced relief of
overall IBS symptoms, abdominal pain/discomfort, and
improvement in abnormal bowel habits compared with
the baseline period and graded them on a 5-point ordinate
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QOL25 every 4 weeks by using the Japanese version of the
IBS quality of life (IBS-QOL) measurement instrument26
(Supplementary Material).Efﬁcacy and Safety End Points
The primary end point was monthly responder rates
of improvement in stool consistency in the ﬁrst month.
Drug efﬁcacy in the ﬁrst month is critical for IBS-D pa-
tients because lack of efﬁcacy during this period moti-
vates patients to seek alternative therapies.27 Patients
with weekly mean BSFS scores of 3 to 5 during the 1
week of the treatment period and a decrease of 1 point
in mean BSFS scores from the baseline period were
deﬁned as weekly responders. Patients who were weekly
responders for at least 2 of the 4 weeks in 1 month were
considered monthly responders. If more than 2 daily
scores were missing during any week of the study
period, the mean score for that week was deﬁned as
missing. Patients with missing mean BSFS scores were
regarded as weekly nonresponders.
Secondary end points included monthly responder
rates of global assessment of relief of overall IBS symp-
toms, relief of abdominal pain/discomfort, and
improvement in abnormal bowel habits. Patients with
scores of 0 or 1 at each weekly evaluation point were
deﬁned as weekly responders, and patients who were
weekly responders for at least 2 of the 4 weeks in 1
month were considered to be monthly responders. Scales
measuring IBS symptoms, including severity of abdom-
inal pain/discomfort, BSFS, stool frequency, urgency and
feeling of incomplete evacuation, and IBS-QOL, were
established for the secondary end points. All adverse
events were recorded during the intervention period.Statistical Analysis
Statistical analysis was performed by using SAS Drug
Development (version 3.4) and PC-SAS (version 9.1.3) (SAS
Institute Inc, Cary, NC). Sample sizes were calculated to
provide90%power todetect a19.2%difference inmonthly
responder rates of improvement in stool consistency dur-
ing theﬁrstmonthbetween the2groups (18.9%and38.1%
for the placebo and ramosetron groups, respectively) that
were based on a preliminary clinical study (Clinicaltrials.
gov ID: NCT00918411, unpublished data) by using the c2
test with a 2-sided signiﬁcance level of .05.
In total, 260 patients (130 patients/group) were
selected for randomization. Efﬁcacy analyses included
the full analysis set (FAS), which was as complete as
possible and as close as possible to the intention-to-treat
ideal of including all randomized subjects.28 The FAS
included all patients who received at least 1 dose of the
study drug during the treatment period and in whom >1
end point could be evaluated. To determine the robust-
ness of the results, primary analyses were performedaccording to the per-protocol set. Safety analyses were
performed for all patients who received at least 1 dose of
the study drug during the treatment period.
Monthly responder rates of improvement in stool
consistency during the ﬁrst month are expressed as a
percentage of responders, and 95% conﬁdence intervals
(CIs) are presented. The treatment groups were compared
by using the c2 test with a 2-sided signiﬁcance level of .05.
Relative risk (RR) and number needed to treat (NNT)
were then calculated. Other monthly responder rate
parameters were similarly analyzed. Weekly changes in
the severity of abdominal pain/discomfort and stool
frequency, percentage of days without urgency, and
percentage of days without a sense of incomplete evacu-
ation were evaluated by using the t test. For comparing
ramosetron with placebo, analysis of covariance was
performed with the treatment groups as a factor and
baseline scores as covariates to measure changes in the
overall IBS-QOL and IBS-QOL subscale scores at each
evaluation point from the baseline.
Results
Overall Study Population
Figure 1 shows a ﬂowchart of patient progression.
Analyses were performed by using data from 148
placebo-treated and 147 ramosetron-treated patients.
Among these, 10 and 18 patients in the ramosetron and
placebo groups, respectively, discontinued treatment
prematurely. Reasons for premature discontinuation are
listed in Figure 1 (also Supplementary Material).
The demographic and baseline characteristics of all
randomized patients were comparable (Table 1). Treat-
ment compliance was 97.5% and 98.4% in the ramose-
tron and placebo groups, respectively. No statistically
signiﬁcant difference in the demographic and baseline
characteristics was observed between the groups.
Therefore, the study data were not adjusted statistically.
Evaluation of the Primary End Point
Monthly responder rates of improvement in stool con-
sistency in the ﬁrstmonth (primary end point) were 50.3%
(95% CI, 42.0–58.7) and 19.6% (95% CI, 13.5–26.9) in the
ramosetron and placebo groups, respectively (difference,
30.7%; 95%CI, 20.4–41.1; P< .001; Figure 2). RRwas 2.57
(95% CI, 1.79–3.70), and NNT was 3.25 (95% CI,
2.44–4.89). Monthly responder rates at all evaluation
points were signiﬁcantly higher in the ramosetron group
than in the placebo group (Supplementary Figure 1).
Evaluation of Secondary End Points
All monthly responder rates of global assessment of
relief of overall IBS symptoms (Figure 3A) and relief of
abdominal pain/discomfort (Figure 3B) were signiﬁcantly
Figure 1. Flowchart of pa-
tient progress throughout
the study. Reasons for
dropping out of the study
are shown.
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all evaluation points.
Changes in the severity of abdominal pain/discomfort
from baseline per week were 0.78  0.82 (mean 
standard deviation [SD]) in the ramosetron groupTable 1. Demographics and Baseline Characteristics of the
Treatment Groups
Patient background
Placebo
(n ¼ 148)
Ramosetron
(n ¼ 147)
P
value
Age (y) 40.2  10.1 40.9  10.6 .58
Duration of disease (mo) 164.4  134.4 155.0  134.2 .55
Severity of abdominal pain/
discomfort
1.8  0.7 1.72  0.6 .22
Stool form (appearance) 5.7  0.4 5.7  0.4 .95
Stool frequency 2.9  1.4 2.9  1.6 .91
IBS-QOL-Japanese
Overall 67.3  18.7 70.4  16.0 .14
Dysphoria 57.9  23.1 61.3  21.2 .19
Interference with activity 55.5  22.5 58.6  20.6 .20
Body image 84.4  17.5 87.4  14.5 .10
Health worry 70.4  21.4 73.9  19.2 .15
Food avoidance 59.7  28.1 63.5  26.8 .24
Social reaction 80.7  19.4 82.1  16.0 .50
Sexual concerns 86.1  18.2 88.5  16.5 .23
Relationship 71.7  23.8 74.6  21.1 .26
NOTE. Data are expressed as means  SD.and 0.60  0.86 in the placebo group at the last point.
At week 5, a signiﬁcant reduction was observed in the
ramosetron group (0.70  0.73) compared with the
placebo group (0.48  0.75, P ¼ .012). BSFS scores
were signiﬁcantly lower in the ramosetron group (4.9 
0.8 at week 1 and 4.8  1.0 at the last point) than in the
placebo group (5.4  0.7 at week 1 and 5.2  0.8 at the
last point, P < .001) throughout the treatment period
(Figure 3C). Changes in stool frequencies from baseline
per week were signiﬁcantly greater in the ramosetronFigure 2.Monthly responder rates of improvement in stool
consistency. Column height: responder rate (%). Error bar:
95% CI. P values were calculated by using the c2 test.
Figure 3. Secondary end points. (A) Monthly responder rates
for relief of overall IBS symptoms. (B) Monthly responder
rates for relief of abdominal pain/discomfort. P values were
calculated by using the c2 test. (C) Weekly changes in BSFS
scores. Line graph: means  SD. *P < .01, **P < .001
compared with placebo.
Figure 4. Changes in overall scores on the Japanese version
of IBS-QOL from baseline to week 4. ***P < .001 compared
with placebo.
Table 2. Incidence of Adverse Events
Event
Placebo
(n ¼ 149)
Ramosetron
(n ¼ 147)
P
value
All adverse events 77 (51.7) 69 (46.9) .48
Blood and lymphatic system
disorders
1 (0.7) 3 (2.0) .37
Anemia 1 (0.7) 3 (2.0) .37
Gastrointestinal disorders 21 (14.1) 21 (14.3) 1.00
Constipation 1 (0.7) 5 (3.4) .12
Hard stool 2 (1.3) 12 (8.2) .01
Hepatobiliary disorders 5 (3.4) 3 (2.0) .72
Hepatic dysfunction 5 (3.4) 3 (2.0) .72
Infections and infestations 39 (26.2) 29 (19.7) .21
Gastroenteritis 2 (1.3) 4 (2.7) .45
Nasopharyngitis 25 (16.8) 20 (13.6) .52
Investigations 21 (14.1) 13 (8.8) .20
Increased serum alanine
aminotransferase
7 (4.7) 3 (2.0) .34
Increased serum bilirubin 3 (2.0) 3 (2.0) 1.00
Nervous system disorders 4 (2.7) 4 (2.7) 1.00
Headache 1 (0.7) 3 (2.0) .37
NOTE. Data are expressed as numbers (%). Events with an incidence of 2%
in the ramosetron group are listed. P values were calculated by using Fisher
exact test.
June 2014 Ramosetron for IBS-D 957group (0.47  0.80 at week 1 and 0.57  1.10 at the
last point) than in the placebo group (0.26  0.61 at
week 1, P ¼ .014 and 0.27  1.13 at the last point, P ¼
.023) (Supplementary Figure 2).
In analyses of IBS-QOL, greater improvements in HR-
QOL were observed in the ramosetron group than in the
placebo group (Figure 4). Signiﬁcantly greater improve-
ments in overall IBS-QOL scores were observed in the
ramosetron group at weeks 4 (13.7, [12.0–15.4]),
adjusted mean [95% CI]), 8 (15.9 [13.9–17.9]), and 12
(17.5 [15.4–19.6]) and at the last point (16.8
[14.7–18.8]) than in the placebo group (9.2 [7.5–10.8]), P
< .001; (11.7 [9.7–13.7]), P ¼ .003; (13.3 [11.1–15.4]),
P ¼ .007; (12.4 [10.4–14.4]), P ¼ .003, respectively
(Supplementary Figure 3).Safety
Safety was evaluated in all 296 patients, with adverse
events occurring in 46.9% and 51.7% of ramosetron and
placebo patients, respectively (Table 2). The incidence of
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group (8.2%) than in the placebo group (1.3%, P ¼ .006).
Ramosetron also induced constipation in 3.4% patients.
However, the incidence was not signiﬁcantly higher than
that in the placebo group (0.7%). RR of constipation was
5.07 (95% CI, 0.60–42.86). All episodes of constipation
and hard stools in the ramosetron group, assumed to be
caused by the pharmacologic actions of ramosetron,
were classiﬁed as mild and resolved early without using
rescue drugs (Supplementary Material).Discussion
Ramosetron is more potent and selective than other
5-HT3 antagonists.
16 Previous reports have shown su-
perior efﬁcacy of ramosetron compared with placebo in
male IBS-D patients,19,20 and the mechanism is believed
to be inhibition of 5-HT3 receptor antagonism in the
myenteric plexus and vagal afferent neurons.29 Ramo-
setron showed the same clinical effects as the anticho-
linergic drug mebeverine in an open-labeled trial.23
Moreover, the incidence of constipation was much
lower in ramosetron-treated patients than in alosetron-
treated or cilansetron-treated patients.22,23 Here, RR
(95% CI) of constipation was 5.07 (0.60–42.86) in the
ramosetron group, and no signiﬁcant increase in con-
stipation was observed. Conversely, meta-analysis of other
5-HT3 antagonists found RR (95% CI) of constipation to be
4.89 (3.6–6.56) and 2.92 (1.85–4.63) in alosetron-treated
and cilansetron-treated patients, respectively.14 In the
present study and previous trials,19,20,23 ramosetron was
administered to 901 IBS-D patients in total. Among these,
no ischemic colitiswas reported.Meta-analysis of alosetron
and cilansetron indicated ischemic colitis in 9 of 4337 pa-
tients (0.2%).14 Its high potential, high selectivity, clear
efﬁcacy, and lower incidence of serious adverse events
suggest that ramosetron is the most promising therapeutic
agent for IBS-D.
After failure to demonstrate efﬁcacy in male IBS-D
patients,30 alosetron was approved and indicated for
limited use only in female IBS-D patients.13,22 Hence,
most subsequent clinical trials of alosetron and cilanse-
tron have been performed in female IBS-D subjects.14,24
Conversely, ramosetron has been approved only for
male IBS-D patients in Japan,20,22 Korea,23 and Thailand,
according to the results of a phase III trial that demon-
strated no signiﬁcant effect in female IBS-D patients,20
mainly because of its small sample size. The present
data conﬁrmed the clinical effect of ramosetron in male
IBS-D patients, and it is natural to assume that ramose-
tron would be effective regardless of ethnicity. Further-
more, RR values for alosetron and cilansetron have been
reported to be lower in studies including only women
(1.23 [1.14–1.32]) compared with studies including both
sexes or only men (1.39 [1.28–1.51]; RR ratio, 0.88
[0.79–0.99]).14 However, larger trials with both men and
women are required to resolve these gender differences.IBS-QOL is a reliable and well-validated instrument
for assessing HR-QOL in IBS patients.25 Although most
linear end points have no established minimal clinically
important difference (MCID) as a benchmark, MCIDs of
IBS-QOL lie between 10 and 14.31 In this study, IBS-QOL
scores of the ramosetron group improved beyond the
MCID benchmark at all time points, whereas those of the
placebo group did not always improve beyond the MCID
benchmark. Regardless of the QOL measure, appropriate
administration of 5-HT3 antagonists to IBS-D patients is
likely to induce a clinically meaningful improvement.
This study has some limitations. In contrast with
most IBS clinical trials from Western countries,13,24 the
present study was limited to men. However, even in
Western countries, the prevalence of IBS in men is high.2
In the present study, inclusion criteria and responder
deﬁnition on stool consistency and abdominal pain/
discomfort were not exactly the same as those in FDA
proposal.21 They may be considered in a future study
(Supplementary Material).
In conclusion, the present data indicate that ramo-
setron is superior to placebo in improving stool consis-
tency with a low incidence of adverse events in male
IBS-D patients. The results also indicate that ramose-
tron improves HR-QOL in IBS-D patients. Thus, ramose-
tron is suggested to be the most promising agent among
the currently available 5-HT3 antagonists for treating
IBS-D.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2013.11.024.References
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Supplementary Material
Methods
Patient population. Male outpatients aged 20–64 years
who were diagnosed according to the Rome III criteria
were eligible. In brief, IBS was deﬁned by recurrent
abdominal pain/discomfort for at least 3 days/month in
the last 3 months, which was associated with 2 of the
following: improvement with defecation, onset associated
with a change in frequency of stools, and/or onset asso-
ciated with a change in the form (appearance) of stools.
Patients were eligible if they fulﬁlled the criteria for the
last 3 months, with symptom onset at least 6 months
before diagnosis. IBS-D was deﬁned as having loose
(mushy) orwatery stools for>25%of the time andhard or
lumpy stools for <25% of bowel movements. Organic
diseases were excluded by total colonoscopy or double-
contrast barium enema in patients aged 50 years and
colonoscopy, sigmoidoscopy, or barium enema in patients
aged <50 years. These examinations were performed
within 5 years before the provisional registration of sub-
jects and after the onset of IBS symptoms.
According to medical interview conducted by
attending physicians before provisional registration, pa-
tients were excluded if any of the following were evident:
a history of resection of the stomach, small intestine, or
large intestine (excluding appendicitis or resection of
benign polyps); history or current evidence of inﬂam-
matory bowel disease; history or current evidence of
ischemic colitis, concurrent infectious enteritis, hyper-
thyroidism, hypothyroidism, or other diseases that may
affect gastrointestinal transit or colonic function; history
or current evidence of abuse of drugs or alcohol within
the previous year and malignant tumors; current evi-
dence of severe depression or a severe anxiety disorder
that could potentially affect the evaluation of study drug
efﬁcacy; concurrent serious cardiovascular, respiratory,
renal, hepatic, gastrointestinal (excluding IBS), blood, or
neurological/psychiatric diseases; or history of drug al-
lergies. In addition, patients were excluded if they were
using drugs or undergoing examinations that could affect
the evaluation of study drug efﬁcacy; if they had been
enrolled in previous clinical studies of ramosetron or had
taken ramosetron within 3 months (12 weeks) before
provisional registration; and if they were participating or
had participated in other clinical studies within 12 weeks
before study initiation.
Data collection. During the baseline and treatment
periods, patients recorded their IBS symptoms daily on
paper diary cards at each bedtime.
Severity of abdominal pain/discomfort was assessed
daily by using a 5-point ordinate scale (0, none; 1, mild;
2, moderate; 3, severe; and 4, intolerable). Stool consis-
tency was classiﬁed by using the BSFS1 as follows: type
1, separate hard lumps like nuts (difﬁcult to pass); type
2, sausage-shaped but lumpy; type 3, like a sausage but
with cracks on its surface; type 4, like a sausage or snake,
smooth and soft; type 5, soft blobs with clear-cut edges
(passed easily); type 6, ﬂuffy pieces with ragged edges
(mushy stool); and type 7, watery, no solid pieces, and
entirely liquid. Urgency and feelings of incomplete
evacuation were assessed by using a binary scale (0,
absent or 1, present). Relief of overall IBS symptoms and
abdominal pain/discomfort were graded according to a
5-point ordinate scale (0, completely relieved; 1,
considerably relieved; 2, somewhat relieved; 3, un-
changed; and 4, worsened). Improvement in abnormal
bowel habits was scored by using a 5-point ordinate
scale (0, nearly normalized; 1, considerably relieved; 2,
somewhat relieved; 3, unchanged; and 4, worsened).
Results
Overall study population. In total, 296 of 471 patients
who provided written informed consent to participate in
the study were randomized during the treatment period.
Of those who dropped out of the study before random-
ization, 148 did not satisfy the inclusion or exclusion
criteria, 20 withdrew consent, 2 were judged unable to
be kept under observation, 1 was excluded for protocol
violation, and 4 were excluded for other reasons. Of 296
patients who were randomized to the treatment groups,
147 patients were allocated to the ramosetron group and
149 to the placebo group. One patient in the placebo
group was excluded from the FAS because no efﬁcacy
variable was measured after administration of the study
drug.
An FAS was used in this study, as deﬁned in the ICH
E92 generated by the regulatory authorities and phar-
maceutical industries of the European Union, United
States, and Japan based on each party’s agreement. The
FAS is designed to be as complete as possible and as
close as possible to the intention-to-treat ideal of
including all randomized subjects. In this study, 1 patient
with no data after randomization was excluded from the
analysis set. The patient was unable to participate in the
study because of his busy schedule, and there was no
relationship between discontinuation and the treatment
itself. The decision to exclude this patient from the
analysis set was taken before unblinding, according to
the predeﬁned procedure stipulated in the study proto-
col. Hence, exclusion of this patient from the analysis set
caused no bias. Only 1 patient was reasonably excluded
from the study. Therefore, the quality of this study as a
whole is high, and drug efﬁcacy was evaluated
appropriately.
Evaluation of the primary end point. Regarding weekly
responder rates, signiﬁcant improvements were ach-
ieved in the ramosetron group compared with the pla-
cebo group at all weeks except at week 9
(Supplementary Figure 1). These results suggest a rapid
and sustainable treatment effect of ramosetron on
improvement of stool consistency in IBS-D patients.
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Evaluation of secondary end points. Improvement in
abnormal bowel habits (Supplementary Figure 2) was
signiﬁcantly higher in the ramosetron group than in the
placebo group at all evaluation points.
At baseline, the percentage of days without urgency
was 43.1%  30.8% and 39.8%  30.7% in the ramo-
setron and placebo groups, respectively. The percentage
of days without urgency increased at week 1 (61.5% 
31.7%) and at the last point (70.7%  33.4%) in the
ramosetron group compared with the placebo group (at
week 1: 50.4%  34.7%, P ¼ .004; at the last point:
61.0%  36.6%, P ¼ .018). Similarly, at baseline, the
percentage of days without incomplete evacuation was
45.0%  36.8% and 42.7%  38.4% in the ramosetron
and placebo groups, respectively. The percentage of days
without incomplete evacuation increased from week 5
(64.8%  36.7%) to week 9 (64.5%  37.6%) in the
ramosetron group. This percentage was signiﬁcantly
higher than that in the placebo group (week 5: 51.8% 
39.3%, P ¼ .004; week 9: 54.8%  41.2%, P ¼ .043).
In IBS-QOL analysis, all subscale scores except those
for sexual concerns (whose baseline was the highest of
all 8 subscales) were signiﬁcantly improved in the
ramosetron group at week 4 (Supplementary Figure 3).
Among the 8 subscales, scores for dysphoria, interfer-
ence with activity, food avoidance, social reaction, and
relationship clearly and signiﬁcantly improved in the
ramosetron group compared with the placebo group at
weeks 4, 8, and 12 and the ﬁnal point.
Safety. Other adverse events that had a frequency of
>2% in the ramosetron group included headache, naso-
pharyngitis, gastroenteritis, anemia, hepatic dysfunction,
increased serum alanine aminotransferase, and increased
serum bilirubin. These adverse events are shown in
Table 2 in main text. No death or serious/severe adverse
events were observed in the ramosetron group. Almost all
adverse events in the ramosetron group were mild and
resolved spontaneously. Drug-related adverse events that
had an incidence of >1% in the ramosetron group
included abdominal distention, epigastralgia, con-
stipation, hard stool, anemia, hepatic dysfunction,
increased serum alanine aminotransferase, and increased
serum bilirubin. All these drug-related adverse events
were mild, except for 1 case of moderate epigastralgia.
Discussion
This study demonstrated the efﬁcacy of ramosetron
in improving stool consistency as a primary end point in
male IBS-D patients. The results are in accordance with
those of previous clinical studies involving ramosetron
and also demonstrate the below points. First, our data
indicated ﬂexible drug development in IBS according to
the characteristics of the drug. Global improvement
measures, such as adequate relief or satisfactory relief of
symptoms, are often used in IBS clinical trials; however,
some arguments have been made regarding this method
of assessment.3 Second, improvements in IBS-QOL scores
due to ramosetron administration were clearly observed
in male IBS-D patients. Although similar ﬁndings were
recently reported with alosetron,4 subjects in that study
were all female, and the study used a different QOL
measure for IBS. Third, ramosetron is a readily available
5-HT3 antagonist in East Asia and is associated with a
very low incidence of ischemic colitis or other serious
adverse events.5 Fourth, although the clinical effects of
ramosetron have not been clearly demonstrated in fe-
male IBS-D patients,6 the efﬁcacy of this drug in male
IBS-D patients provides a medical rationale for its use in
other subsets of IBS-D patients. No new treatment has
been approved for use in male IBS-D patients in Western
countries since 2000. Thus, our ﬁndings support our
main hypothesis regarding the superiority of ramosetron
over the placebo in improving stool consistency, with a
low incidence of serious adverse events. The ﬁndings
support the additional hypothesis that ramosetron had
positive effects on HR-QOL in male IBS-D patients.
In other clinical trials of drug treatments for IBS,
global assessment has been used as a primary end point.7
Typical measurement constructs for global assessment
include adequate relief, satisfactory relief, 5-point ordi-
nate scales of improvement, or 7-point ordinate scales of
improvement.3,6,8–11 Previous clinical trials of ramose-
tron have demonstrated improvement in global assess-
ment by using a 5-point ordinate scale.6,10 In a phase III
trial, ramosetron was superior to the placebo, with a
difference in efﬁcacy of 20% for global improvement of
IBS symptoms, of 12% for adequate relief of abdominal
pain/discomfort, and of 20% for improvement of
abnormal bowel habits.6
In the present study, these clinical effects of ramo-
setron were suggested to be related to improvement of
stool consistency. This is a scientiﬁcally logical conclu-
sion that is based on the mechanism of action of ramo-
setron on 5-HT3 receptors in the myenteric plexus.
12,13
Ramosetron may relieve abdominal pain/discomfort by
antagonizing the exaggerated motility of the lower gut
and the increased tone of the smooth muscles of the gut
in response to meals,14 distention,14,15 or stressors.12,16
Because 5-HT3 in the myenteric plexus plays a key role
in the generation of peristalsis and in diarrhea,17 using
improvement in stool consistency as the primary end
point is a rational approach.
According to FDA guidance, drugs for IBS should be
speciﬁcally developed to treat the co-primary end points
of abdominal pain and abnormal defecation.18 However,
this guidance permits investigators to design trials with
only 1 of these end points if the mechanism of action of
the drug applies to only 1 of these symptoms.18
Demonstration of signiﬁcant and clinically meaningful
changes in the targeted single end point could serve as a
basis for approval, as long as the other important
symptom or sign did not worsen on treatment.18 These
study data combined with the data of other studies
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provide evidence that improvement in stool consistency
can be used as a single primary end point or a co-
primary end point with the evaluation of global assess-
ment of relief of overall IBS symptoms in clinical trials of
the 5-HT3 antagonist for IBS-D patients.
The inclusion criteria and the deﬁnition of a
responder on stool consistency in this study are almost
consistent with the FDA guidance on IBS issued in
2010.19 However, in 2012, the FDA issued a revised
guidance that modiﬁed the inclusion criteria to require at
least 2 days per week with a BSFS of 6 or 7.18 The
revised guidance also modiﬁed the responder deﬁnition
to require at least a 50% reduction in the number of days
per week with a type 6 or 7 BSFS.18 For abdominal pain
or discomfort there were several differences from both
the 201019 and 201218 guidance of FDA. The scale used
in the study was a 5-point ordinate scale rather than 11
points as recommended by the FDA.18,19 The inclusion
criterion used in this study was a weekly average of at
least 0.7 on the 0–4 scale, whereas the inclusion criterion
for both the 2010 and 2012 FDA guidance was an
average of 3 or higher on a 0–10 point scale.18,19 The
responder deﬁnition in this study for pain/discomfort
was an average weekly pain/discomfort rating of 1 or
less on a 0–4 scale, whereas the pain responder deﬁni-
tion for the 201019 and 201218 FDA guidance was a 30%
reduction in the average intensity of abdominal pain or
discomfort. These facts do not undercut the importance
of the ﬁndings, but it is suggested that the FDA moved
the goal posts in the process of this study and that
delicately modiﬁed protocol from the newest FDA guid-
ance18 is also useful for drug development in the world.
IBS-QOL is a reliable and well-validated instrument
for assessing HR-QOL in IBS patients.20 The reliability
and validity of the Japanese version of IBS-QOL have
been established.21 IBS-speciﬁc HR-QOL improvement
was also demonstrated in a previous study in which
alosetron was administered to female IBS-D patients.4
However, that study used IBSQOL, which differs from
IBS-QOL. Regardless of the QOL measure, appropriate
administration of 5-HT3 antagonists to IBS-D patients is
likely to induce clinically meaningful improvement.
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Supplementary Figure 2.Monthly responder rate of
improvement in abnormal bowel habits. Column height:
responder rate (%). Error bar: 95% CI. Open column: placebo
group (n ¼ 148). Black column: ramosetron group (n ¼ 147).
P values were calculated by using the c2 test.
Supplementary Figure 1.Weekly responder rate of
improvement in stool consistency. Line graph: responder rate
(%). Error bar: 95% CI. Thin line: placebo group (n ¼ 148).
Thick black line: ramosetron group (n ¼ 147). *P < .01, **P <
.001, compared with the placebo. P values were calculated
by using the c2 test.
Supplementary Figure 3. Changes in all subscale scores of
the Japanese version of IBS-QOL from baseline to week 4.
Column height: the values adjusted by using the baseline
value as a covariate. Error bar: 95% CI. Open column: pla-
cebo group (n ¼ 148). Black column: ramosetron group (n ¼
147). *P < .05, **P < .01, ***P < .001, compared with the
placebo. P values were calculated by using analysis of
covariance, with the treatment groups as a factor and base-
line score as a covariate.
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